SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2

(2021) Shourong Wang et al.   Cell Death & Disease

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Aberrant Expression of RAD52, Its Prognostic Impact in Rectal Cancer and Association with Poor Survival of Patients

(2020) Vincent Ho et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

SF3b4: A Versatile Player in Eukaryotic Cells

(2020) Feng Xiong et al.   Frontiers in Cell and Developmental Biology

SF3B4 Plays an Oncogenic Role in Esophageal Squamous Cell Carcinoma

(2020) SHINYA KIDOGAMI et al.   ANTICANCER RESEARCH

Roles and mechanisms of alternative splicing in cancer — implications for care

(2020) Sophie C. Bonnal et al.   Nature Reviews Clinical Oncology

Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity

(2020) Ilenia Pellarin et al.   ONCOGENE

Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation

(2020) Pooja Popli et al.   Cell Death & Disease

Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy

(2019) Tomoki Yamano et al.   Oncotarget

Epithelial ovarian cancer

(2019) Stephanie Lheureux et al.   LANCET

SF3B2-mediated RNA splicing drives human prostate cancer progression

(2019) Norihiko Kawamura et al.   CANCER RESEARCH

Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma

(2019) Ping Li et al.   Cancer Cell International

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies

(2019) Toma et al.   Cancers

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells

(2018) Katherine Sullivan-Reed et al.   Cell Reports

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

(2018) André Kahles et al.   CANCER CELL

SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma

(2018) Zhiyong Liu et al.   EBioMedicine

miR-509-3p enhances platinum drug sensitivity in ovarian cancer

(2018) Leilei Niu et al.   GENE

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells

(2017) Wentao Zhou et al.   TUMOR BIOLOGY

Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer

(2016) Ke Chen et al.   CLINICAL CANCER RESEARCH

Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations

(2016) Constantin Cretu et al.   MOLECULAR CELL

miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer

(2016) Yinghong Pan et al.   Oncotarget

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer

(2015) K-F Hsu et al.   BRITISH JOURNAL OF CANCER

Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus

(2015) Rachel Lieberman et al.   MOLECULAR CARCINOGENESIS

Splicing proofreading at 5′ splice sites by ATPase Prp28p

(2013) Fei Yang et al.   NUCLEIC ACIDS RESEARCH

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF

(2010) Ryohei Furumai et al.   CANCER SCIENCE

Expansion of the eukaryotic proteome by alternative splicing

(2010) Timothy W. Nilsen et al.   NATURE

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells

(2009) B. J. Albert et al.   MOLECULAR CANCER THERAPEUTICS

Most mammalian mRNAs are conserved targets of microRNAs

(2008) R. C. Friedman et al.   GENOME RESEARCH